Infections with the coronavirus disease of 2019 (COVID-19) can result in a variety of consequences, including problems with the central nervous system (CNS). COVID-19 encephalopathy, a condition marked by cognitive problems, altered consciousness, and even convulsions, is one of the most typical COVID-19 CNS side effects. A recently authorized mRNA-based vaccination called Moderna COVID-19 is intended to stop COVID-19 infections and related consequences. Here, we describe two patients who developed encephalopathy and seizures after receiving part one of their Moderna COVID-19 vaccine series but had no previous neurological or psychiatric history. By addressing confounders in our patients, we propose a cause for this issue and thoroughly explore how the Moderna vaccination may be to blame. Soon after the second injection, the Moderna vaccine against COVID-19 demonstrated better than 90% efficacy. According to studies, protective immunity lasts for six months with relatively minor declines. However, researchers are still trying to figure out how vaccination-induced immunity to the virus evolves and shifts over time. Immunity, according to researchers, depends on robust immunological responses from T cells and neutralizing antibodies. To recognize and defend the body against diseases that have already been encountered, memory T cells remain in the body.
The Moderna COVID-19 vaccine is permitted for use in an emergency as a:
Primary series of two doses for people six months of age and older.
- For individuals 6 months of age and older who have been determined to have specific types of immunocompromise, the third dosage of the primary series.
- First dose of the booster for anyone over the age of 18 at least five months after finishing a primary series of the Spikevax or the Moderna COVID-19 vaccination.
- For those who are 18 years of age or older and have finished their main vaccination with another COVID-19 vaccine that has been authorized or approved. This initial booster dosage should be administered at the same intervals as those permitted for a booster dose of the original vaccine.
- Second booster dose of any certified or approved COVID-19 vaccination for those 50 years of age or older at least four months after receiving a first booster dose.
- Second booster dose of any permitted or approved COVID-19 vaccination for anyone aged 18 and older with specific immunocompromise at least 4 months after receiving a first booster dose.
According to CDC, The COVID-19 vaccine from Moderna (Spikevax) gained U.S. for people aged 18 and above, Food and Drug Administration (FDA) approval on January 31, 2022. Vaccines can be marketed under brand names once they have received FDA approval. The Moderna COVID-19 vaccine is sold under the trade name Spikevax. Moderna COVID-19, a vaccination for people aged 18 and older that has received FDA approval, will now be marketed under the name Spikevax. The vaccine’s formulation has not changed as a result of the name change. Since the vaccine is allowed (but not yet approved) for people aged 6 months to 17 years, the name “Moderna” will continue to be used for this age range.